Stock Research for BIOVF

BIOVF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BIOVF Stock Chart & Research Data

The BIOVF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOVF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BIOVF Due diligence Resources & Stock Charts

The BIOVF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIOVF Detailed Price Forecast - CNN Money CNN View BIOVF Detailed Summary - Google Finance
Yahoo View BIOVF Detailed Summary - Yahoo! Finance Zacks View BIOVF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BIOVF Trends & Analysis - Trade-Ideas Barrons View BIOVF Major Holders - Barrons
NASDAQ View BIOVF Call Transcripts - NASDAQ Seeking View BIOVF Breaking News & Analysis - Seeking Alpha
Spotlight View BIOVF Annual Report - CompanySpotlight.com OTC Report View BIOVF OTC Short Report - OTCShortReport.com
TradeKing View BIOVF Fundamentals - TradeKing Charts View BIOVF SEC Filings - Bar Chart
WSJ View Historical Prices for BIOVF - The WSJ Morningstar View Performance/Total Return for BIOVF - Morningstar
MarketWatch View the Analyst Estimates for BIOVF - MarketWatch CNBC View the Earnings History for BIOVF - CNBC
StockMarketWatch View the BIOVF Earnings - StockMarketWatch MacroAxis View BIOVF Buy or Sell Recommendations - MacroAxis
Bullish View the BIOVF Bullish Patterns - American Bulls Short Pains View BIOVF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BIOVF Stock Mentions - StockTwits PennyStocks View BIOVF Stock Mentions - PennyStockTweets
Twitter View BIOVF Stock Mentions - Twitter Invest Hub View BIOVF Investment Forum News - Investor Hub
Yahoo View BIOVF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIOVF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BIOVF - SECform4.com Insider Cow View Insider Transactions for BIOVF - Insider Cow
CNBC View BIOVF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIOVF - OTC Markets
Yahoo View Insider Transactions for BIOVF - Yahoo! Finance NASDAQ View Institutional Holdings for BIOVF - NASDAQ


Stock Charts

FinViz View BIOVF Stock Insight & Charts - FinViz.com StockCharts View BIOVF Investment Charts - StockCharts.com
BarChart View BIOVF Stock Overview & Charts - BarChart Trading View View BIOVF User Generated Charts - Trading View




Latest Financial News for BIOVF


Sobi™ to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth
Posted on Monday November 12, 2018

STOCKHOLM, Nov. 13, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1]), consisting of USD 1,000 M (SEK 9.1 B) in cash and USD 500 M (SEK 4.5 B) equivalent in newly issued Sobi shares.


Invitation - Presentation of Sobi's Q3 2018 Results
Posted on Tuesday October 23, 2018

STOCKHOLM , Oct. 23, 2018 /PRNewswire/ -- On 31 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2018. Financial analysts and media are invited ...


What Does Swedish Orphan Biovitrum AB (publ)’s (STO:SOBI) Ownership Structure Look Like?
Posted on Thursday September 13, 2018

If you want to know who really controls Swedish Orphan Biovitrum AB (publ) (STO:SOBI), then you’ll have to look at the makeup of its share registry. Institutions often own sharesRead More...


Sobi™ Completes Acquisition of the Global Rights for Emapalumab From Novimmune
Posted on Thursday August 23, 2018

STOCKHOLM, August 23, 2018 /PRNewswire/ -- Following approvals from relevant competition authorities, Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has completed the acquisition of the perpetual global rights to emapalumab from Novimmune SA. That Sobi had entered into an exclusive licence agreement for the acquisition of the perpetual global rights to emapalumab was announced on 20 July 2018. Emapalumab is a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis (HLH), developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.